Related Experiment Video
Updated: May 22, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Deciphering biased-agonism complexity reveals a new active AT1 receptor entity
Aude Saulière1, Morgane Bellot, Hervé Paris
1Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, Université Toulouse III Paul Sabatier, Toulouse, France.
Researchers developed new probes to study G protein-coupled receptor (GPCR) signaling. They found that a biased agonist, [(1)Sar(4)Ile(8)Ile]-angiotensin II (SII), actually stabilizes a distinct G protein-dependent receptor module.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- Functional selectivity of G protein-coupled receptors (GPCRs) is a key characteristic, but complex signaling pathways hinder its understanding.
- Deciphering GPCR functional selectivity is challenging due to pleiotropic and crosstalk signaling.
- Understanding the initial active receptor conformation is crucial for decoding biased agonism.
Purpose of the Study:
- To develop novel, highly sensitive bioluminescence resonance energy transfer (BRET)-based probes for direct detection of G protein activation across all isoforms.
- To investigate the G protein-coupling activity of [(1)Sar(4)Ile(8)Ile]-angiotensin II (SII), a previously characterized biased agonist.
- To elucidate the precise signaling mechanism of SII at the angiotensin II type 1 (AT(1)) receptor.
Main Methods:
- Development of specific and sensitive BRET-based probes for real-time monitoring of G protein activation.
- Multiplexing assays to simultaneously measure receptor conformation and downstream signaling events.
- Evaluation of SII's G protein-coupling activity in both recombinant and primary cell systems.
Main Results:
- SII was identified as an agonist that stabilizes a unique G protein-dependent AT(1A) receptor signaling module.
- This SII-induced signaling module is distinct from that mediated by the physiological agonist, angiotensin II.
- The study provides direct evidence of G protein activation by SII, challenging previous assumptions of its G protein independence.
Conclusions:
- Biased agonists may not simply select a subset of effects from a physiological agonist but can stabilize novel, distinct active receptor conformations.
- The developed BRET probes offer a powerful tool for dissecting complex GPCR signaling and functional selectivity.
- This research redefines the understanding of biased agonism, highlighting the potential for creating new pharmacological receptor entities.
More Related Videos
12:03Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.